Physician profile
Volha Daniel
NPI 1720730096
$3,830.00
in general payments reported to CMS, 2019-2025
30 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $613 · 2023: $580 · 2024: $920 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $498.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $479.70 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $361.45 | 2022-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $313.35 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.18 | 2022-2025 | |
| Lilly USA, LLC | $252.65 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $235.64 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $225.64 | 2025 | Breztri, Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $136.25 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $134.81 | 2022-2025 | Keveyis, Gvoke Hypopen |
| Abbvie INC. | $117.81 | 2025 | |
| Astellas Pharma US INC | $111.11 | 2024-2025 | Veozah |
| Esperion Therapeutics, INC. | $80.37 | 2024-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $75.74 | 2025 | |
| Janssen Pharmaceuticals, INC | $57.62 | 2022-2024 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.02 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $51.83 | 2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $47.16 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $42.68 | 2022 | |
| Corcept Therapeutics | $41.61 | 2025 | Korlym |
| Abbott Laboratories | $40.76 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $29.27 | 2022 | |
| Boston Scientific Corporation | $25.97 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.96 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $23.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.02 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.40 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $21.13 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $14.97 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Volha Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.